Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederroche.com
Investor Update
Get the latest updates from Investor Update directly as they happen.
Follow now 341 followers
Latest posts
Last updated about 19 hours ago
Roche provides update on Phase III OCREVUS high dose study in people with relapsing multiple sclerosis
about 19 hours ago
MUSETTE trial was designed to determine whether a higher dose of the...
Roche’s Greenhouse Gas Reduction Targets Validated by the Science Based Targets initiative (SBTi)
1 day ago
Roche has received the validation of its near-term and long-term greenhouse gas...
Reminder: Invitation to Roche’s Virtual Neurology Investor Event
6 days ago
We are pleased to invite investors and analysts to participate in our...
Roche Annual General Meeting 2025
9 days ago
Shareholders approved all proposals of the Board of Directors Severin Schwan was...
Invitation to Roche’s First Quarter Sales 2025 Presentation
10 days ago
Roche will publish its Sales Results for the 1st Quarter 2025 prior...
Roche to share latest scientific advancements from its neuromuscular portfolio at Muscular Dystrophy Association (MDA) 2025 conference
17 days ago
New Evrysdi five-year data from the SUNFISH study showed continued stabilisation of...
Roche enters into an exclusive collaboration & licensing agreement with Zealand Pharma to co-develop and co-commercialise petrelintide as a potential foundational therapy for people with overweight and obesity
22 days ago
Agreement allows for a range of potentially best-in-class therapy options as monotherapy...
FDA accepts supplemental Biologics License Application for Roche’s Gazyva/Gazyvaro for the treatment of lupus nephritis
29 days ago
Gazyva/Gazyvaro is the only anti-CD20 monoclonal antibody in a randomised phase III...
Invitation to Roche’s Virtual Neurology Investor Event
about 1 month ago
We are pleased to invite investors and analysts to participate in our...
Phase III study shows Xolair may be more effective with fewer side effects than oral immunotherapy for the treatment of food allergies
about 1 month ago
First-ever head-to-head trial comparing Xolair and oral immunotherapy (OIT) Results were featured...
CHMP recommends EU approval of Roche’s Columvi combination for people with relapsed or refractory diffuse large B-cell lymphoma
about 1 month ago
Columvi plus chemotherapy showed a 41% reduction in the risk of death...
Roche unveils a new class of next-generation sequencing with its novel sequencing by expansion technology
about 1 month ago
Roche's innovative sequencing by expansion (SBX) technology represents a leap forward in...